New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 15, 2014
04:55 EDTHPTX, HPTXHyperion Therapeutics management to meet with Leerink
Meeting to be held in Baltimore on August 20 hosted by Leerink.
News For HPTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
16:22 EDTHPTXOn The Fly: Closing Wrap
Subscribe for More Information
13:48 EDTHPTXHyperion Therapeutics downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
12:47 EDTHPTXHyperion Therapeutics downgraded to Neutral from Outperform at Wedbush
Subscribe for More Information
12:22 EDTHPTXOn The Fly: Midday Wrap
Subscribe for More Information
11:49 EDTHPTXStreet Check: Hyperion bought after Brean noted takeout potential last month
Subscribe for More Information
11:02 EDTHPTXHyperion Therapeutics downgraded to Hold from Buy at Brean Capital
Brean Capital downgraded Hyperion Therapeutics (HPTX) citing the takeover by Horizon Pharma (HZNP). Brean views the buyout price as "reasonable and fair."
07:02 EDTHPTXHorizon Pharma to host conference call
Conference call to discuss the acquisition of Hyperion Therapeutics (HPTX) will be held on March 30 at 8 am. Webcast Link
06:04 EDTHPTXHorizon Pharma to acquire Hyperion Therapeutics for $46.00 per share
Subscribe for More Information
06:01 EDTHPTXHorizon Pharma to acquire Hyperion Therapeutics for $46.00 per share
Subscribe for More Information
March 26, 2015
08:43 EDTHPTXHyperion Therapeutics management to meet with Needham
Meetings to be held in Detroit/Chicago on March 31 and in Chicago on April 1 hosted by Needham.
March 25, 2015
11:01 EDTHPTXHyperion Therapeutics price target raised to $51 from $40 at Brean Capital
Subscribe for More Information
March 23, 2015
11:16 EDTHPTXHyperion Therapeutics price target raised to $52 from $36 at Wedbush
Wedbush raised Hyperion's price target to $52 ahead of the hepatic encephalopathy Phase III trial of Ravicti and the likelihood of success. Shares are Outperform rated.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use